Preliminary evidence for the combined efficacy of focused ultrasound blood–brain barrier opening and Re-1 delivery for anxiety and memory improvement in a 3xTg-Alzheimer's disease mouse model

Abstract

The aim of this preliminary study is to evaluate the efficacy of early intervention with Focused Ultrasound-induced Blood–Brain Barrier Opening (FUS-BBBO) and Re-1 delivery for anxiety amelioration, memory improvement, and pathology reduction in an Alzheimer's Disease (AD) mouse model. FUS-BBBO was applied and Re-1 delivered to the hippocampi of presymptomatic, male triple transgenic (3xTg)-AD mice using a preventative paradigm of 10 total biweekly treatments over the course of 5 months. Following treatment, the animals underwent five days of behavioral testing for anxiety, spatial memory, and reversal learning. The combination of FUS-BBBO and Re-1 delivery showed evidence of improving the long-term spatial memory and short-term reversal learning with no significant effect on amyloid and tau accumulation. The small sample size is a limiting factor for this preliminary study, which still offers promising indications in support of early intervention with amyloid-targeting Re-1 and FUS-BBBO for cognitive and minor pathological improvement in AD.

Graphical abstract: Preliminary evidence for the combined efficacy of focused ultrasound blood–brain barrier opening and Re-1 delivery for anxiety and memory improvement in a 3xTg-Alzheimer's disease mouse model

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Communication
Submitted
28 Feb 2025
Accepted
12 Aug 2025
First published
19 Aug 2025
This article is Open Access
Creative Commons BY-NC license

RSC Pharm., 2025, Advance Article

Preliminary evidence for the combined efficacy of focused ultrasound blood–brain barrier opening and Re-1 delivery for anxiety and memory improvement in a 3xTg-Alzheimer's disease mouse model

R. L. Noel, S. L. Gorman, A. J. Batts, D. Tsakri, D. A. Jimenez, M. Pelecanou, M. Sagnou and E. E. Konofagou, RSC Pharm., 2025, Advance Article , DOI: 10.1039/D5PM00059A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements